Recce Pharmaceuticals Advances clinical programs in Q1 FY23
- Recce Pharmaceuticals (RCE) has multiple trials in the pipeline following the September quarter
- RCE reported no serious adverse effects in the seventh cohort who were dosed with 6000mg of its R327 drug and the positive outcomes will see a phase 1b/2a early-stage sepsis efficacy study begin before the end of the year
- Additional clinical trials are set to begin including a phase two UTI trial and phase two study on diabetic foot ulcer infections
- After net cash outflows of $5.86 million, Recce had $5.7 million in cash and 0.97 quarters left of funding but will soon receive an R&D tax incentive estimated to be more than $3.5 million
- Company shares are down 3.55 per cent to close at 68 cents
